Based on the data, the trial’s safety committee determined 360 mg/m² as the optimal dose for subsequent testing. Among eight trial participants who were treated at or above this dose, four responded to therapy, and two had stable disease. Two of the responders were penta-refractory, and they lived without signs of disease worsening for 4.5 months.

The most common adverse events were thrombocytopenia (low platelet levels), neutropenia (low neutrophil levels), diarrhea, and nausea. One dose-limiting toxicity was reported: a case of severe neutropenia in a person treated at the highest dose level.